Deans' stroke musings

Changing stroke rehab and research worldwide now.Time is Brain!Just think of all the trillions and trillions of neurons that DIE each day because there are NO effective hyperacute therapies besides tPA(only 12% effective). I have 493 posts on hyperacute therapy, enough for researchers to spend decades proving them out. These are my personal ideas and blog on stroke rehabilitation and stroke research. Do not attempt any of these without checking with your medical provider. Unless you join me in agitating, when you need these therapies they won't be there.

What this blog is for:

Shortly after getting out of the hospital and getting NO information on the process or protocols of stroke rehabilitation and recovery I started searching on the internet and found that no other survivor received useful information. This is an attempt to cover all stroke rehabilitation information that should be readily available to survivors so they can talk with informed knowledge to their medical staff. It's quite disgusting that this information is not available from every stroke association and doctors group.
My back ground story is here:http://oc1dean.blogspot.com/2010/11/my-background-story_8.html

Thursday, February 13, 2014

Gout Culprit Promising as Acute Stroke Tx - Uric acid

Will this be enough proof to have this as a standard stroke protocol? Who is going to roll this out?
http://www.medpagetoday.com/MeetingCoverage/ISCNeuroEdition/44276?
Uric acid given along with thrombolytics in the first hours after an ischemic stroke showed a signal for improved recovery, a Spanish proof-of-concept trial showed.
The rate of near full recovery at 90 days was 39.3% with the powerful antioxidant compared with 33% on placebo instead, Angel Chamorro, MD, PhD, of the Hospital Clinic in Barcelona, Spain, and colleagues reported here at the International Stroke Conference.
That 23% relative reduction in risk of a modified Rankin score greater than 1, reflecting poor functional outcome, at 90 days didn't reach statistical significance in the 421-patient URICO-ICTUS Study (P=0.099).
But the magnitude of reduction in median modified Rankin score -- 3 points on uric acid versus 2 on placebo (P=0.045) -- was on par with recombinant tissue plasminogen activator (rtPA) in the pivotal trial, Chamorro argued.

More at link.

No comments:

Post a Comment